Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Monday session in red amid volatile trading. The shares closed down -1.04 points or -2.01% at $50.70 with 1.01 billion shares getting traded. Post opening the session at $51.51, the shares hit an intraday low of $50.58 and an intraday high of $51.61 and the price vacillated in this range throughout the day. The company has a market cap of $51.37 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) on September 19, 2016 announced top-line results from the exploratory Phase 2 PRIDE-HD study. This was a 52-week, dose-ranging trial of pridopidine twice daily versus placebo, in the treatment of Huntington disease (HD). The study was directed at measuring improvement in motor function and the effect on HD progression.
An unusually high placebo effect, extending beyond that expected from previous studies, limited the ability to determine treatment effects on assessments of HD motor scores. Evidence of symptomatic impact, however, was seen in the early stage HD patient sub-population, with improvement in Total Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient sub-set (stage 1 HD) at specific doses.
The discovery of pridopidine’s previously unknown mode of action as a potent agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study design, from a 26-week study focused on symptoms, to a 52-week study focused on exploring pridopidine’s potential impact on disease progression, as measured by Total Functional Capacity (TFC). TFC is the most widely accepted and validated tool for assessing disease stage in HD. It has been used as the endpoint in more than 10 previous clinical trials of drugs seeking to demonstrate an impact on HD progression, none of which were successful.
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) ended Monday session in red amid volatile trading. The shares closed down -0.39 points or -0.85% at $45.73 with 1.96 billion shares getting traded. Post opening the session at $46.30, the shares hit an intraday low of $45.63 and an intraday high of $46.35 and the price vacillated in this range throughout the day. The company has a market cap of $92.42 billion and the numbers of outstanding shares have been calculated to be 1.96 billion shares.
On Sept. 15, 2016 Novo Nordisk is one of the 2016 Best Workplaces for Women, according to global research and consulting firm Great Place to Work® and Fortune.
Novo Nordisk ranked #66 on the list, which is based on employees’ assessments of communications with management, options for development and training, and support for work/life balance, among other factors. The ranking also takes into account how well-represented women are within the workforce overall and in management and executive positions.
Both women and men at Best Workplaces for Women feel their employers provide ample opportunities to grow and advance in their careers, and provide them with the flexibility they want to balance their work and personal lives.
“Driving change to improve the lives of the 29 million Americans with diabetes begins with our people,” said Jacqueline Scanlan, Corporate Vice President, Human Resources. “Novo Nordisk Inc. is proud to be named as one of the Best Workplaces for Women. We strive every day to create an environment where all employees are engaged, supported, and able to balance their work with their personal commitments and interests.”
“There’s a strong correlation between being able to talk openly with company executives and feeling like a workplace is fair,” said Michael C. Bush, CEO of Great Place to Work®. “Traditionally, communication channels with leaders have been less available to women than to men. The Best Workplaces for Women do well at paving the way for those open dialogs, and as a result, women are more likely to feel they get fair consideration in their jobs and careers. Congratulations to these great companies—they are showing everyone how to create a Great Place to Work For ALL.”